Summary:
Click image to enlarge
CYPRESS is a Phase 2 clinical study evaluating the safety and efficacy of RTA 901
(an oral investigational drug) in patients with Diabetic Peripheral Neuropathic Pain (DPNP).
Qualified Participants Must:
• Male/Female ≥ 18 years of age
•
Diagnosed with T1DM or T2DM ≥ 1 year prior to screening. 6+ months of chronic pain relating to DPN
•
Clinical diagnosis of DPNP - in lower extremities, may include pain that is burning, lancinating, tingling, or shooting (electric shock–like).
•
Currently taking only 1 allowed prescribed SOC pain medication for managing DPN
Qualified Participants May Receive:
All study related care at no cost
Compensation for time and travel